newsfilter
← Latest News
GlobeNewswire·

NeOnc CEO Amir F. Heshmatpour to Address Global Life Sciences Investment at Abu Dhabi Future Health Summit 2026

  • NeOnc Technologies Holdings, Inc. announced that Executive Chairman, President & CEO Amir F. Heshmatpour will speak at the Abu Dhabi Future Health Summit 2026 from October 20 to 22 at the ADNEC Centre in the UAE.
  • Heshmatpour will join a panel titled "The Investment Lens: Banking on Prediction" on October 22 to discuss investment in predictive healthcare, clinical financing, & international collaboration.
  • NeOnc is expanding its UAE clinical development presence following Department of Health – Abu Dhabi authorizations for its lead programs NEO100 & NEO212 in June 2026.
  • The company is establishing NuroMENA as a regional collaboration platform to support CNS oncology pipeline advancement & pursue partnerships with local stakeholders.
  • Regulatory approvals granted in June 2026 include IND authorization for NEO100 across multiple adult & pediatric protocols for recurrent IDH1-mutant high-grade glioma, as well as IND clearance for NEO212.
  • Heshmatpour brings over 25 years of experience in finance & M&A, having led transactions totaling over $1.5 billion in IPOs & exceeding $5 billion in private funding & acquisitions.
  • NeOnc is a clinical-stage biopharmaceutical company developing intranasal NEO100 & oral NEO212 for CNS cancers, utilizing intellectual property licensed from the University of Southern California.
  • Neither NEO100 nor NEO212 has received FDA approval for commercial use, & the company focuses on generating clinical evidence to address unmet patient needs.